EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Drug-tolerant persisting polyploid giant cancer cells mediate resistance to HER2-targeting antibody-drug conjugates

Narjes Yazdi, Negar Pourjamal, Riku Katainen, Juho Väänänen, Jun Dai, Anna Vähärautio, Jorma Isola, Minna Kempas, Vadim Le Joncour, Pirjo Laakkonen, Heikki Joensuu, Mark Barok

Cancer Letters · 2025-10 · 630 · 217900

DOI: 10.1016/j.canlet.2025.217900 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2025-10. Verfasst von Narjes Yazdi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Laboratory of Molecular Oncology, University of Helsinki, Helsinki, Finla…. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Drug Resistance, Neoplasm, Immunoconjugates, Breast Neoplasms. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Polyploid giant cancer cells (PGCCs) contribute to resistance against various cancer therapies. This study investigates whether HER2-directed antibody-drug conjugates (ADC) induce PGCCs and their role in drug resistance. HER2-positive breast cancer (JIMT-1) and gastric cancer (MKN7, SNU-216) cells were treated with HER2-directed ADCs, trastuzumab emtansine, trastuzumab deruxtecan, XMT-1522, and disitamab vedotin (DV). The induced persister cells were characterized using live cell imaging, confocal microscopy, immunohistochemistry, flow cytometry, gene expression analysis, SNP genotyping, and next-generation sequencing. Drug sensitivity was assessed using the AlamarBlue assay and SCID mouse xenografts. All 4 ADCs induced PGCCs, with XMT-1522 and DV being the most effective. The induced giant cells were drug-resistant and exhibited drug-tolerant persister cell characteristics. HER2 protein levels were downregulated in persisting drug-tolerant PGCCs and their daughter cells. JIMT-1 cells lost HER2 amplification following XMT-1522 treatment, along with the loss of extrachromosomal DNA containing HER2. However, XMT-1522-treated MKN7 and SNU-216 cells, and DV-treated JIMT-1 cells, retained the amplicon. Drug-tolerant PGCCs upregulated nectin-4, and treatment with enfortumab vedotin, a nectin-4-targeted ADC, inhibited the regrowth of JIMT-1 xenografts. ADC treatment induces PGCCs that contribute to drug resistance. ADC-induced drug-tolerant PGCCs express nectin-4, which may serve as a potential therapeutic target.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Erb-b2 Receptor Tyrosine KinasesDrug Resistance, NeoplasmImmunoconjugatesBreast NeoplasmsStomach NeoplasmsHumansAnimalsFemaleCell Line, TumorXenograft Model Antitumor AssaysMiceMice, SCIDPolyploidyTrastuzumabAdo-Trastuzumab EmtansineAntibodies, Monoclonal, HumanizedCamptothecin

Stichwörter der Autor:innen

Antibody drug conjugateDisitamab vedotinExtrachromosomal DNAHuman epithelial growth factor receptor-2Nectin-4Polyploid giant cancer cellsXMT-1522

Substanzen

Erb-b2 Receptor Tyrosine KinasesImmunoconjugatesTrastuzumabAdo-Trastuzumab EmtansineAntibodies, Monoclonal, HumanizedCamptothecinERBB2 protein, humantrastuzumab deruxtecan

Autor:innen und Institutionen

  • Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Laboratory of Molecular Oncology, University of Helsinki, Helsinki, Finland.
  • Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland; Applied Tumor Genomics Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland; iCAN Digital P…
  • Applied Tumor Genomics Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
  • Research Program in Systems Oncology, Research Programs Unit, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
  • Research Program in Systems Oncology, Research Programs Unit, Faculty of Medicine, University of Helsinki, Helsinki, Finland; Foundation for the Finnish Cancer Institute, Helsinki, Finland.
  • Laboratory of Cancer Biology, Medical Faculty, University of Tampere, Tampere, Finland.

Zitieren

APA

Yazdi, N., Pourjamal, N., Katainen, R., Väänänen, J., Dai, J., Vähärautio, A., Isola, J., Kempas, M., Le Joncour, V., Laakkonen, P., Joensuu, H., & Barok, M. (2025). Drug-tolerant persisting polyploid giant cancer cells mediate resistance to HER2-targeting antibody-drug conjugates. Cancer Letters, 630, 217900. https://doi.org/10.1016/j.canlet.2025.217900

Vancouver

Yazdi N, Pourjamal N, Katainen R, Väänänen J, Dai J, Vähärautio A, et al. Drug-tolerant persisting polyploid giant cancer cells mediate resistance to HER2-targeting antibody-drug conjugates. Cancer Letters. 2025;630:217900. doi:10.1016/j.canlet.2025.217900

BibTeX
@article{Yazdi2025,
  author = {Yazdi, Narjes and Pourjamal, Negar and Katainen, Riku and Väänänen, Juho and Dai, Jun and Vähärautio, Anna and Isola, Jorma and Kempas, Minna and Le Joncour, Vadim and Laakkonen, Pirjo and Joensuu, Heikki and Barok, Mark},
  title = {Drug-tolerant persisting polyploid giant cancer cells mediate resistance to HER2-targeting antibody-drug conjugates},
  journal = {Cancer Letters},
  year = {2025},
  volume = {630},
  pages = {217900},
  doi = {10.1016/j.canlet.2025.217900}
}
Kostenlos starten →